Combined effect of soy isoflavones and vitamin D3 on bone loss in ovariectomized rats

Nutrition

Volumn 29, Issue 1, 2013, Pages 250-257

  Chang, Kee Lung ^a   Hu, Yu Chen ^a   Hsieh, Bau Shan ^a   Cheng, Hsiao Ling ^a   Hsu, Hen Wei ^a   Huang, Li Wen ^b   Su, Shu Jem ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

Author keywords

Osteoblasts; Osteoclasts; Ovariectomized rat; Soy isoflavones; Vitamin D3

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AGENTS AFFECTING METABOLISM; ALKALINE PHOSPHATASE; CALCITRIOL; COLECALCIFEROL; ESTRADIOL; INTERLEUKIN 1BETA; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOY ISOFLAVONE EXTRACT; TRANSCRIPTION FACTOR OSTERIX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERALIZATION; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; MARKER GENE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST DIFFERENTIATION FACTOR GENE; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PREVENTION STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TRABECULAR BONE; TREATMENT DURATION;

ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY; CHOLECALCIFEROL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ESTRADIOL; FEMALE; HUMANS; INTERLEUKIN-1BETA; ISOFLAVONES; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SOYBEANS; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84870806840     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.03.009     Document Type: Article

References (41)

1. Manolagas S.C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010, 31:266-300.
2. Kaye E.K. Bone health and oral health. J Am Dent Assoc 2007, 138:616-619.
3. Bowring C.E., Francis R.M. National Osteoporosis Society's position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. Menopause Int 2011, 17:63-65.
4. Boyce B.F., Yamashita T., Yao Z., Zhang Q., Li F., Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab 2005, 23(suppl):11-15.
5. Ribot C., Tremollieres F. [Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk]. Presse Med 2006, 35:1557-1563.
6. Udell J.A., Fischer M.A., Brookhart M.A., Solomon D.H., Choudhry N.K. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006, 21:765-771.
7. Messina M.J., Wood C.E. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008, 7:17.
8. Cederroth C.R., Auger J., Zimmermann C., Eustache F., Nef S. Soy, phyto-oestrogens and male reproductive function: a review. Int J Androl 2010, 33:304-316.
9. Arjmandi B.H. The role of phytoestrogens in the prevention and treatment of osteoporosis in ovarian hormone deficiency. J Am Coll Nutr 2001, 20:398S-402.
10. Reddy Vanga S., Good M., Howard P.A., Vacek J.L. Role of vitamin D in cardiovascular health. Am J Cardiol 2010, 106:798-805.
11. van Driel M., Koedam M., Buurman C.J., Hewison M., Chiba H., Uitterlinden A.G., et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 2006, 20:2417-2419.
12. Sutton A.L., Zhang X., Dowd D.R., Kharode Y.P., Komm B.S., Macdonald P.N. Semaphorin 3B is a 1,25-dihydroxyvitamin D3-induced gene in osteoblasts that promotes osteoclastogenesis and induces osteopenia in mice. Mol Endocrinol 2008, 22:1370-1381.
13. Swami S., Krishnan A.V., Peehl D.M., Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005, 241:49-61.
14. Chang K.L., Hung T.C., Hsieh B.S., Chen Y.H., Chen T.F., Cheng H.L. Zinc at pharmacologic concentrations affects cytokine expression and induces apoptosis of human peripheral blood mononuclear cells. Nutrition 2006, 22:465-474.
15. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Itoh K., Ueno Y., et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141:3478-3484.
16. Zou W., Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 2002, 17:1211-1218.
17. Bellows C.G., Aubin J.E., Heersche J.N., Antosz M.E. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 1986, 38:143-154.
18. Park C.J., Zhao Z., Glidewell-Kenney C., Lazic M., Chambon P., Krust A., et al. Genetic rescue of nonclassical ERalpha signaling normalizes energy balance in obese Eralpha-null mutant mice. J Clin Invest 2011, 121:604-612.
19. Roepke T.A., Bosch M.A., Rick E.A., Lee B., Wagner E.J., Seidlova-Wuttke D., et al. Contribution of a membrane estrogen receptor to the estrogenic regulation of body temperature and energy homeostasis. Endocrinology 2010, 151:4926-4937.
20. Ohtomo T., Uehara M., Penalvo J.L., Adlercreutz H., Katsumata S., Suzuki K., et al. Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures. Eur J Nutr 2008, 47:273-279.
21. Garcia-Palacios V., Chung H.Y., Choi S.J., Sarmasik A., Kurihara N., Lee J.W., et al. Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1. Bone 2007, 40:316-322.
22. Ishimi Y., Yoshida M., Wakimoto S., Wu J., Chiba H., Wang X., et al. Genistein, a soybean isoflavone, affects bone marrow lymphopoiesis and prevents bone loss in castrated male mice. Bone 2002, 31:180-185.
23. Ohta A., Uehara M., Sakai K., Takasaki M., Adlercreutz H., Morohashi T., et al. A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice. J Nutr 2002, 132:2048-2054.
24. Zhang Y., Li Q., Wan H.Y., Helferich W.G., Wong M.S. Genistein and a soy extract differentially affect three-dimensional bone parameters and bone-specific gene expression in ovariectomized mice. J Nutr 2009, 139:2230-2236.
25. Chiang S.S., Pan T.M. Antiosteoporotic effects of Lactobacillus -fermented soy skim milk on bone mineral density and the microstructure of femoral bone in ovariectomized mice. J Agric Food Chem 2011, 59:7734-7742.
26. Cai D.J., Zhao Y., Glasier J., Cullen D., Barnes S., Turner C.H., et al. Comparative effect of soy protein, soy isoflavones, and 17beta-estradiol on bone metabolism in adult ovariectomized rats. J Bone Miner Res 2005, 20:828-839.
27. Yamori Y., Moriguchi E.H., Teramoto T., Miura A., Fukui Y., Honda K.I., et al. Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: a ten-week study. J Am Coll Nutr 2002, 21:560-563.
28. Wu J., Oka J., Tabata I., Higuchi M., Toda T., Fuku N., et al. Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. J Bone Miner Res 2006, 21:780-789.
29. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M., et al. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J Bone Miner Res 2008, 23:715-720.
30. Wong W.W., Lewis R.D., Steinberg F.M., Murray M.J., Cramer M.A., Amato P., et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial. Am J Clin Nutr 2009, 90:1433-1439.
31. Levis S., Strickman-Stein N., Ganjei-Azar P., Xu P., Doerge D.R., Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med 2011, 171:1363-1369.
32. Pilsakova L., Riecansky I., Jagla F. The physiological actions of isoflavone phytoestrogens. Physiol Res 2010, 59:651-664.
33. Stein G.S., Lian J.B., van Wijnen A.J., Stein J.L., Montecino M., Javed A., et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004, 23:4315-4329.
34. Edwards J.R., Mundy G.R. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 2011, 7:235-243.
35. Walsh N.C., Gravallese E.M. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010, 233:301-312.
36. Li C., Yang Z., Li Z., Ma Y., Zhang L., Zheng C., et al. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-kappaB and MAPK signaling pathways. J Bone Miner Res 2011, 26:644-656.
37. Luchin A., Purdom G., Murphy K., Clark M.Y., Angel N., Cassady A.I., et al. The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts. J Bone Miner Res 2000, 15:451-460.
38. Tanaka Y., Nakayamada S., Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:325-328.
39. Tanaka Y., Okada Y., Nakamura T. Inter- and intracellular signaling in secondary osteoporosis. J Bone Miner Metab 2003, 21:61-66.
40. Hu Y.C., Cheng H.L., Hsieh B.S., Huang L.W., Huang T.C., Chang K.L. Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function. Bone 2012, Epub ahead of print.
41. D OG, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004;63:354-9.